董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alastair Riddell | 男 | Independent Director | 73 | 10.80万美元 | 未持股 | 2023-05-15 |
| Terry Coelho | 女 | Independent Director | 61 | 11.93万美元 | 未持股 | 2023-05-15 |
| James Sapirstein | 男 | President, Chief Executive Officer, Chairman and Non-Independent Director | 61 | 64.57万美元 | 未持股 | 2023-05-15 |
| Edward J. Borkowski | 男 | Lead Independent Director | 63 | 11.37万美元 | 未持股 | 2023-05-15 |
| Charles J. Casamento | 男 | Independent Director | 77 | 10.37万美元 | 未持股 | 2023-05-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sarah Romano | 女 | Chief Financial Officer | 43 | 43.97万美元 | 未持股 | 2023-05-15 |
| James Sapirstein | 男 | President, Chief Executive Officer, Chairman and Non-Independent Director | 61 | 64.57万美元 | 未持股 | 2023-05-15 |
董事简历
中英对照 | 中文 | 英文- Alastair Riddell
-
Alastair Riddell在2015年9月加入董事会。自2012年9月起，里德尔博士曾担任Definigen有限公司的董事长，并自2013年11月起曾担任Silence Therapeutics有限公司的董事长及从2009年10月至2012年11月Procure Therapeutics的董事长。从2007年至2009年，他担任Stem Cell Sciences公司的首席执行官及2005至2007年，他曾担任Paradigm Therapeutics的首席执行官。从1998至2005年里德尔博士曾担任Pharmagene实验室有限公司的首席执行官。
Alastair Riddell,was appointed to the Board in September 2015. From June 2016 to February 2023, Dr. Riddell served as Chair and Director of Nemesis Biosciences Ltd and previously Chair of Feedback plc (LON: FDBK). He has also served as Chair of the South West Academic Health Science network in the UK since January 2016. Since his appointment in December 2015, Dr. Riddell has served as Non-Executive Director of Cristal Therapeutics in The Netherlands. From September 2012 to February 2016, he served as Chair of Definigen Ltd., and from November 2013 to September 2015 as Chair of Silence Therapeutics Ltd., and from October 2009 to November 2012 as Chair of Procure Therapeutics. Between 2007 to 2009, Dr. Riddell served as the Chief Executive Officer of Stem Cell Sciences plc. and between 2005 to 2007, served at Paradigm Therapeutics Ltd. as the Chief Executive Officer. Between 1998 to 2005, Dr. Riddell also served as the Chief Executive Officer of Pharmagene plc. Dr. Riddell began his career as a doctor in general practice in a variety of hospital specialties and holds a Master of Science and a Bachelor of Medicine and Surgery degrees. He was awarded a Doctorate of Science, Honoris Causa by Aston University in 2016. - Alastair Riddell在2015年9月加入董事会。自2012年9月起，里德尔博士曾担任Definigen有限公司的董事长，并自2013年11月起曾担任Silence Therapeutics有限公司的董事长及从2009年10月至2012年11月Procure Therapeutics的董事长。从2007年至2009年，他担任Stem Cell Sciences公司的首席执行官及2005至2007年，他曾担任Paradigm Therapeutics的首席执行官。从1998至2005年里德尔博士曾担任Pharmagene实验室有限公司的首席执行官。
- Alastair Riddell,was appointed to the Board in September 2015. From June 2016 to February 2023, Dr. Riddell served as Chair and Director of Nemesis Biosciences Ltd and previously Chair of Feedback plc (LON: FDBK). He has also served as Chair of the South West Academic Health Science network in the UK since January 2016. Since his appointment in December 2015, Dr. Riddell has served as Non-Executive Director of Cristal Therapeutics in The Netherlands. From September 2012 to February 2016, he served as Chair of Definigen Ltd., and from November 2013 to September 2015 as Chair of Silence Therapeutics Ltd., and from October 2009 to November 2012 as Chair of Procure Therapeutics. Between 2007 to 2009, Dr. Riddell served as the Chief Executive Officer of Stem Cell Sciences plc. and between 2005 to 2007, served at Paradigm Therapeutics Ltd. as the Chief Executive Officer. Between 1998 to 2005, Dr. Riddell also served as the Chief Executive Officer of Pharmagene plc. Dr. Riddell began his career as a doctor in general practice in a variety of hospital specialties and holds a Master of Science and a Bachelor of Medicine and Surgery degrees. He was awarded a Doctorate of Science, Honoris Causa by Aston University in 2016.
- Terry Coelho
-
Terry Coelho于2021年8月11日加入我们的董事会。Coelho女士曾担任BioDelivery Sciences International, Inc.的执行副总裁兼首席财务官。纳斯达克:BDSI，一家商业阶段的专业制药公司，自2021年1月以来。她于2019年1月加入BDSI，担任首席财务官兼财务主管。在BDSI任职之前，Coelho女士于2017年10月至2018年10月担任拜切公司（纳斯达克代码:BCPC）的首席财务官兼财务主管。任职Balchem公司之前，她曾担任Diversey，Inc.（从希悦尔包装有限公司分离出来的数十亿美元的全球私人股本公司）的首席运营官。2014年10月至2017年8月，她还在Diversey Care担任高级财务职位，包括部门首席财务官和全球商业卓越副总裁。2007年至2014年，Coelho女士还曾在领先的全球组织（包括Mars，Incorporated和Novartis Pharmaceuticals）担任高级财务和运营领导职务，并承担越来越多的责任，包括担任肿瘤发展融资全球主管。Coelho女士拥有巴西IBMEC的金融MBA学位，以及华盛顿特区美国大学国际服务学院的经济学和国际关系文学学士学位，并以优异成绩获得该学位。她曾领导女性网络ERGS，也是首席财务官领导委员会（位于北卡罗来纳州夏洛特）分会的创始指导委员会成员。
Terry Coelho,was appointed to the Board on August 11, 2021. Ms. Coelho served as the Executive Vice President, Chief Financial Officer & Chief Business Development Officer of CinCor Pharma, Inc. (NASDAQ: CINC), a clinical stage cardiorenal therapeutics company, from November 2021 to November 2022. Prior to this, Ms. Coelho served as Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a commercial-stage specialty pharmaceutical company, since January 2019. Prior to her tenure at BDSI, Ms. Coelho served as Chief Financial Officer and Treasurer at Balchem Corporation (NASDAQ: BCPC) from October 2017 to October 2018. Previous to her role at Balchem she served as Chief Operating Officer for Diversey, Inc., a multi-billion-dollar global private equity carve-out from Sealed Air Corporation. She additionally held senior finance positions at Diversey Care, including that of Division Chief Financial Officer and VP of Global Commercial Excellence, from October 2014 through August 2017. Ms. Coelho has also served in senior finance and operational leadership roles of increasing responsibility with leading global organizations, including Mars, Incorporated, and Novartis Pharmaceuticals from 2007 to 2014, including serving as Global Head of Oncology Development Finance. Ms. Coelho is a member of the board of directors of HOOKIPA Pharma, Inc. (NASDAQ: HOOK) and serves on the board's audit and compensation committees. Ms. Coelho earned an MBA in Finance from IBMEC in Brazil and a Bachelor of Arts degree in both Economics and International Relations, summa cum laude, from The American University School of International Service in Washington, DC. She has led Women's Networking ERGs and is a founding Steering Committee Member of the CFO Leadership Council - Charlotte, North Carolina, chapter. - Terry Coelho于2021年8月11日加入我们的董事会。Coelho女士曾担任BioDelivery Sciences International, Inc.的执行副总裁兼首席财务官。纳斯达克:BDSI，一家商业阶段的专业制药公司，自2021年1月以来。她于2019年1月加入BDSI，担任首席财务官兼财务主管。在BDSI任职之前，Coelho女士于2017年10月至2018年10月担任拜切公司（纳斯达克代码:BCPC）的首席财务官兼财务主管。任职Balchem公司之前，她曾担任Diversey，Inc.（从希悦尔包装有限公司分离出来的数十亿美元的全球私人股本公司）的首席运营官。2014年10月至2017年8月，她还在Diversey Care担任高级财务职位，包括部门首席财务官和全球商业卓越副总裁。2007年至2014年，Coelho女士还曾在领先的全球组织（包括Mars，Incorporated和Novartis Pharmaceuticals）担任高级财务和运营领导职务，并承担越来越多的责任，包括担任肿瘤发展融资全球主管。Coelho女士拥有巴西IBMEC的金融MBA学位，以及华盛顿特区美国大学国际服务学院的经济学和国际关系文学学士学位，并以优异成绩获得该学位。她曾领导女性网络ERGS，也是首席财务官领导委员会（位于北卡罗来纳州夏洛特）分会的创始指导委员会成员。
- Terry Coelho,was appointed to the Board on August 11, 2021. Ms. Coelho served as the Executive Vice President, Chief Financial Officer & Chief Business Development Officer of CinCor Pharma, Inc. (NASDAQ: CINC), a clinical stage cardiorenal therapeutics company, from November 2021 to November 2022. Prior to this, Ms. Coelho served as Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a commercial-stage specialty pharmaceutical company, since January 2019. Prior to her tenure at BDSI, Ms. Coelho served as Chief Financial Officer and Treasurer at Balchem Corporation (NASDAQ: BCPC) from October 2017 to October 2018. Previous to her role at Balchem she served as Chief Operating Officer for Diversey, Inc., a multi-billion-dollar global private equity carve-out from Sealed Air Corporation. She additionally held senior finance positions at Diversey Care, including that of Division Chief Financial Officer and VP of Global Commercial Excellence, from October 2014 through August 2017. Ms. Coelho has also served in senior finance and operational leadership roles of increasing responsibility with leading global organizations, including Mars, Incorporated, and Novartis Pharmaceuticals from 2007 to 2014, including serving as Global Head of Oncology Development Finance. Ms. Coelho is a member of the board of directors of HOOKIPA Pharma, Inc. (NASDAQ: HOOK) and serves on the board's audit and compensation committees. Ms. Coelho earned an MBA in Finance from IBMEC in Brazil and a Bachelor of Arts degree in both Economics and International Relations, summa cum laude, from The American University School of International Service in Washington, DC. She has led Women's Networking ERGs and is a founding Steering Committee Member of the CFO Leadership Council - Charlotte, North Carolina, chapter.
- James Sapirstein
-
James Sapirstein，自2023年1月起担任Zyversa Therapeutics，Inc.董事会成员。Sapirstein先生目前是First Wave BioPharma公司（纳斯达克：FWBI）的董事长、首席执行官和总裁。Sapirstein先生的职业生涯始于较小的生物技术公司，后来他加入了吉利德科学公司，领导全球营销团队推出Viread（替诺福韦）。2002年，他接受了Serono实验室代谢和内分泌学执行副总裁的职位。后来，在2006年，他成为Tobira Therapeutics, Inc.的创始首席执行官，该公司当时是一家私营公司。Tobira Therapeutics于2016年被艾尔建收购。2012年，Sapirstein先生成为Alliqua，Inc.的首席执行官。此后，他从2014年3月至2018年10月担任Contravir Pharmaceuticals的首席执行官。所有这些都是上市公司。萨皮尔斯坦在担任首席执行官期间的各种活动中，通过风险资本和公开资本市场融资筹集了超过3亿美元。2015年和2016年，他都被提名为安永年度企业家奖的入围者。除了First Wave Bio Pharma的董事会成员，Sapirstein先生目前还在Enochian Biosciences公司（纳斯达克：ENOB）和Blue Water生物技术公司（纳斯达克：BWV）担任董事职务。2017年2月至2019年2月，他担任新泽西州生物制药行业协会BioNJ的董事会主席。此外，他还是BIO（生物技术创新组织）董事会成员，该组织是促进医疗保健领域公共政策和网络的领先生物技术贸易组织，他是该组织新兴公司科理事会成员。
James Sapirstein,has served as a director since March of 2018. Mr. Sapirstein joined the Board after having served over thirty-nine years in the pharmaceutical industry. He is currently the Chairman, President and CEO of First Wave BioPharma (formerly AzurRx BioPharma) and has served as the CEO of ContraVir Pharmaceuticals, Inc. (now Hepion), which is a company specializing in the Hepatitis B space. After beginning his career in 1984 with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its commercial teams in the US and abroad. He held a number of positions at Hoffmann-LaRoche before moving to Bristol Myers Squibb (BMS) in 1996 as the Director of International Marketing in the Infectious Disease group. While at BMS, he worked on several important HIV/AIDS projects, including Secure the Future. Later, Mr. Sapirstein started his career in smaller biotech companies when he joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir). In 2002, he accepted the position of Executive Vice President of Metabolic and Endocrinology for Serono Laboratories before becoming the founding CEO of Tobira Therapeutics in 2006. In 2012, after several years in the infectious diseases space, Mr. Sapirstein became the CEO of Alliqua Therapeutics at Alliqua, Inc. He is also a Board Director for the Emerging Companies Section Governing group of the Biotechnology Innovation Organization (BIO) and the Chairman Emeritus of BIO's New Jersey Chapter (BioNJ). Mr. Sapirstein received his MBA from Fairleigh Dickinson University and his B.Pharm. from Rutgers University. - James Sapirstein，自2023年1月起担任Zyversa Therapeutics，Inc.董事会成员。Sapirstein先生目前是First Wave BioPharma公司（纳斯达克：FWBI）的董事长、首席执行官和总裁。Sapirstein先生的职业生涯始于较小的生物技术公司，后来他加入了吉利德科学公司，领导全球营销团队推出Viread（替诺福韦）。2002年，他接受了Serono实验室代谢和内分泌学执行副总裁的职位。后来，在2006年，他成为Tobira Therapeutics, Inc.的创始首席执行官，该公司当时是一家私营公司。Tobira Therapeutics于2016年被艾尔建收购。2012年，Sapirstein先生成为Alliqua，Inc.的首席执行官。此后，他从2014年3月至2018年10月担任Contravir Pharmaceuticals的首席执行官。所有这些都是上市公司。萨皮尔斯坦在担任首席执行官期间的各种活动中，通过风险资本和公开资本市场融资筹集了超过3亿美元。2015年和2016年，他都被提名为安永年度企业家奖的入围者。除了First Wave Bio Pharma的董事会成员，Sapirstein先生目前还在Enochian Biosciences公司（纳斯达克：ENOB）和Blue Water生物技术公司（纳斯达克：BWV）担任董事职务。2017年2月至2019年2月，他担任新泽西州生物制药行业协会BioNJ的董事会主席。此外，他还是BIO（生物技术创新组织）董事会成员，该组织是促进医疗保健领域公共政策和网络的领先生物技术贸易组织，他是该组织新兴公司科理事会成员。
- James Sapirstein,has served as a director since March of 2018. Mr. Sapirstein joined the Board after having served over thirty-nine years in the pharmaceutical industry. He is currently the Chairman, President and CEO of First Wave BioPharma (formerly AzurRx BioPharma) and has served as the CEO of ContraVir Pharmaceuticals, Inc. (now Hepion), which is a company specializing in the Hepatitis B space. After beginning his career in 1984 with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its commercial teams in the US and abroad. He held a number of positions at Hoffmann-LaRoche before moving to Bristol Myers Squibb (BMS) in 1996 as the Director of International Marketing in the Infectious Disease group. While at BMS, he worked on several important HIV/AIDS projects, including Secure the Future. Later, Mr. Sapirstein started his career in smaller biotech companies when he joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir). In 2002, he accepted the position of Executive Vice President of Metabolic and Endocrinology for Serono Laboratories before becoming the founding CEO of Tobira Therapeutics in 2006. In 2012, after several years in the infectious diseases space, Mr. Sapirstein became the CEO of Alliqua Therapeutics at Alliqua, Inc. He is also a Board Director for the Emerging Companies Section Governing group of the Biotechnology Innovation Organization (BIO) and the Chairman Emeritus of BIO's New Jersey Chapter (BioNJ). Mr. Sapirstein received his MBA from Fairleigh Dickinson University and his B.Pharm. from Rutgers University.
- Edward J. Borkowski
-
Edward J. Borkowski在2015年5月加入公司董事会，2015年9月被任命为公司董事长。在2015年5月Borkowski先生加盟Concordia Healthcare董事会。在2016年2月，他加入了Concordia担任执行副总裁，并继续担任公司董事。2013年9月至2016年2月之间，Borkowski先生是Amerigen Pharmaceuticals，早期阶段，仿制药公司的首席财务官。从2012年5月至2013年6月，Borkowski先生担任ConvaTec Inc.的私人的全球医疗产品和技术公司的财务总监。从2011年1月至2012年5月，Borkowski先生担任顾问和几家涉及医疗技术和仿制药行业投资的私募股权投资公司的顾问。从2009年5月至2010年12月，Borkowski先生担任CareFusion Corporation的首席财务官，一个专注于制药点胶设备，输液泵，呼吸机和手术器械的全球医疗保健公司。从2002年至2009年，Borkowski先生是Mylan Labs，最大的世界之一仿制与专业制药公司的首席财政官。在加入迈伦之前，从1999年开始，他就职于Pharmacia Corporation的Consumer Healthcare Group，该公司与辉瑞公司于2003年担任北美财务与行政部副总裁，随后担任全球财务与信息技术部副总裁。从1992年至1999年，他在惠氏（Wyeth）担任各种财务职位，该公司专门从事药品，消费保健产品和动物保健产品的业务（当时称为美国家庭产品公司）。Borkowski先生从罗格斯大学获得了他的工商管理硕士学位和从阿勒格尼学院获得了他的学士学位。他还是一位注册会计师，美国注册会计师协会和NYSSCPA的成员。
Edward J. Borkowski,was appointed to the Board in May 2015, and currently serves as First Wave Biopharma, Inc. Lead Independent Director. Mr. Borkowski served as Chair of the Board from 2015 through his resignation effective as of February 19, 2021. Mr. Borkowski is a healthcare executive who currently serves as Executive Vice President for Therapeutics MD. He served as Executive Vice President of MiMedx Group, Inc. (Nasdaq: MDGX) from April 2018 until December 2019. Mr. Borkowski also served as a director for Co-Diagnostics, Inc. (Nasdaq: CODX), from May 2017 until June 2019. Previously, he served as the Chief Financial Officer of Aceto Corporation (Nasdaq: ACET) from February 2018 to April 2018, and has held several executive positions with Concordia International, an international specialty pharmaceutical company, between May 2015 to February 2018. Mr. Borkowski has also served as Chief Financial Officer of Amerigen Pharmaceuticals, a generic pharmaceutical company with a focus on oral, controlled release products and as the Chief Financial Officer and Executive Vice President of Mylan N.V. In addition, Mr. Borkowski previously held the position of Chief Financial Officer with Convatec, a global medical device company focused on wound care and ostomy, and Carefusion, a global medical device company for which he helped lead its spin-out from Cardinal Health into an independent public company. Mr. Borkowski has also served in senior financial positions at Pharmacia and American Home Products (Wyeth). He started his career with Arthur Andersen & Co. after receiving his MBA in accounting from Rutgers University subsequent to having earned his degree in Economics and Political Science from Allegheny College. Mr. Borkowski is currently a Trustee and a member of the Executive Committee of Allegheny College. - Edward J. Borkowski在2015年5月加入公司董事会，2015年9月被任命为公司董事长。在2015年5月Borkowski先生加盟Concordia Healthcare董事会。在2016年2月，他加入了Concordia担任执行副总裁，并继续担任公司董事。2013年9月至2016年2月之间，Borkowski先生是Amerigen Pharmaceuticals，早期阶段，仿制药公司的首席财务官。从2012年5月至2013年6月，Borkowski先生担任ConvaTec Inc.的私人的全球医疗产品和技术公司的财务总监。从2011年1月至2012年5月，Borkowski先生担任顾问和几家涉及医疗技术和仿制药行业投资的私募股权投资公司的顾问。从2009年5月至2010年12月，Borkowski先生担任CareFusion Corporation的首席财务官，一个专注于制药点胶设备，输液泵，呼吸机和手术器械的全球医疗保健公司。从2002年至2009年，Borkowski先生是Mylan Labs，最大的世界之一仿制与专业制药公司的首席财政官。在加入迈伦之前，从1999年开始，他就职于Pharmacia Corporation的Consumer Healthcare Group，该公司与辉瑞公司于2003年担任北美财务与行政部副总裁，随后担任全球财务与信息技术部副总裁。从1992年至1999年，他在惠氏（Wyeth）担任各种财务职位，该公司专门从事药品，消费保健产品和动物保健产品的业务（当时称为美国家庭产品公司）。Borkowski先生从罗格斯大学获得了他的工商管理硕士学位和从阿勒格尼学院获得了他的学士学位。他还是一位注册会计师，美国注册会计师协会和NYSSCPA的成员。
- Edward J. Borkowski,was appointed to the Board in May 2015, and currently serves as First Wave Biopharma, Inc. Lead Independent Director. Mr. Borkowski served as Chair of the Board from 2015 through his resignation effective as of February 19, 2021. Mr. Borkowski is a healthcare executive who currently serves as Executive Vice President for Therapeutics MD. He served as Executive Vice President of MiMedx Group, Inc. (Nasdaq: MDGX) from April 2018 until December 2019. Mr. Borkowski also served as a director for Co-Diagnostics, Inc. (Nasdaq: CODX), from May 2017 until June 2019. Previously, he served as the Chief Financial Officer of Aceto Corporation (Nasdaq: ACET) from February 2018 to April 2018, and has held several executive positions with Concordia International, an international specialty pharmaceutical company, between May 2015 to February 2018. Mr. Borkowski has also served as Chief Financial Officer of Amerigen Pharmaceuticals, a generic pharmaceutical company with a focus on oral, controlled release products and as the Chief Financial Officer and Executive Vice President of Mylan N.V. In addition, Mr. Borkowski previously held the position of Chief Financial Officer with Convatec, a global medical device company focused on wound care and ostomy, and Carefusion, a global medical device company for which he helped lead its spin-out from Cardinal Health into an independent public company. Mr. Borkowski has also served in senior financial positions at Pharmacia and American Home Products (Wyeth). He started his career with Arthur Andersen & Co. after receiving his MBA in accounting from Rutgers University subsequent to having earned his degree in Economics and Political Science from Allegheny College. Mr. Borkowski is currently a Trustee and a member of the Executive Committee of Allegheny College.
- Charles J. Casamento
-
Charles J. Casamento，于2017年3月被任命为董事会成员。2007年以来，Casamento先生一直担任The Sage Group（一家医疗保健咨询集团）的执行董事和负责人。此前，从2004年10月到2007年4月，他担任Osteologix（一家初创公司，他监督上市）的总裁兼首席执行官。从1999年到2004年，他是Questcor Pharmaceuticals的创始人，担任总裁、首席执行官和主席。在他任职Questcor期间，公司收购了Acthar，这款产品的销售额最终超过了10亿美元。他也曾担任RiboGene Inc.的总裁、首席执行官和主席，直到1999年RiboGene与另一家公司合并形成Questcor。他也是Indevus（前身为Interneuron Pharmaceuticals）的联合创始人、总裁兼首席执行官，并在Genzyme Corporation担任高级管理职位，在那里他曾担任美国医院供应高级副总裁，在那里他曾担任重症护理部门、Johnson & Johnson、hoffman - laroche和Sandoz的业务发展副总裁。他目前担任Relmada Therapeutics （OTCQB： RLMD）的董事会主席，Eton Pharmaceuticals （Nasdaq： Eton）的董事会成员，PaxMedica, Inc. （Nasdaq： PXMD）的董事会成员，此前担任Catholic Medical Missions Board（大型非营利性国际组织）的董事和副主席。他持有Fordham University的药学学士学位和Iona College的工商管理硕士学位。
Charles J. Casamento,was appointed to Gt Biopharma, Inc. Board of Directors on May 1, 2023. Mr. Casamento is currently executive director and principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. Mr. Casamento was founder of, and from 1999 through 2004, served as chairman of the board, president and CEO, of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt. Mr. Casamento formerly served as RiboGene, Inc.'s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Indevus was eventually acquired by Endo. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. (now Novartis). Mr. Casamento also serves on the board of directors of Eton Pharmaceuticals, Inc. (Nasdaq: ETON), First Wave Biopharma, Inc. (Nasdaq: FWBI) and Relmada Therapeutics, Inc. (Nasdaq: RLMD). During his career he has served on the boards of fourteen Biotech/Pharma companies and has also been a director and vice chairman of The Catholic Medical Missions Board, a large not-for-profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor's degree in Pharmacy from Fordham University and an MBA from Iona University and was originally licensed to practice pharmacy in the states of New York and New Jersey. - Charles J. Casamento，于2017年3月被任命为董事会成员。2007年以来，Casamento先生一直担任The Sage Group（一家医疗保健咨询集团）的执行董事和负责人。此前，从2004年10月到2007年4月，他担任Osteologix（一家初创公司，他监督上市）的总裁兼首席执行官。从1999年到2004年，他是Questcor Pharmaceuticals的创始人，担任总裁、首席执行官和主席。在他任职Questcor期间，公司收购了Acthar，这款产品的销售额最终超过了10亿美元。他也曾担任RiboGene Inc.的总裁、首席执行官和主席，直到1999年RiboGene与另一家公司合并形成Questcor。他也是Indevus（前身为Interneuron Pharmaceuticals）的联合创始人、总裁兼首席执行官，并在Genzyme Corporation担任高级管理职位，在那里他曾担任美国医院供应高级副总裁，在那里他曾担任重症护理部门、Johnson & Johnson、hoffman - laroche和Sandoz的业务发展副总裁。他目前担任Relmada Therapeutics （OTCQB： RLMD）的董事会主席，Eton Pharmaceuticals （Nasdaq： Eton）的董事会成员，PaxMedica, Inc. （Nasdaq： PXMD）的董事会成员，此前担任Catholic Medical Missions Board（大型非营利性国际组织）的董事和副主席。他持有Fordham University的药学学士学位和Iona College的工商管理硕士学位。
- Charles J. Casamento,was appointed to Gt Biopharma, Inc. Board of Directors on May 1, 2023. Mr. Casamento is currently executive director and principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. Mr. Casamento was founder of, and from 1999 through 2004, served as chairman of the board, president and CEO, of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt. Mr. Casamento formerly served as RiboGene, Inc.'s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Indevus was eventually acquired by Endo. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. (now Novartis). Mr. Casamento also serves on the board of directors of Eton Pharmaceuticals, Inc. (Nasdaq: ETON), First Wave Biopharma, Inc. (Nasdaq: FWBI) and Relmada Therapeutics, Inc. (Nasdaq: RLMD). During his career he has served on the boards of fourteen Biotech/Pharma companies and has also been a director and vice chairman of The Catholic Medical Missions Board, a large not-for-profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor's degree in Pharmacy from Fordham University and an MBA from Iona University and was originally licensed to practice pharmacy in the states of New York and New Jersey.
高管简历
中英对照 | 中文 | 英文- Sarah Romano
Sarah Romano于2022年3月1日被任命为First Wave Biopharma，Inc.的首席财务官。Romano女士曾于2017年2月至2022年2月担任Kiora Pharmaceuticals, Inc.（纳斯达克股票代码：KPRX）（原EyeGate Pharmaceuticals，Inc.）的首席财务官，并于2016年8月至2017年1月担任公司财务总监。Kiora Pharmaceuticals，Inc.是一家临床阶段的专业制药公司，致力于开发治疗眼科疾病的产品。在加入Kiora之前，Romano女士于2015年6月至2016年8月担任TechTarget助理财务总监，并于2013年9月至2015年5月担任专注于医疗保健的高管招聘公司Bowdoin Group的公司财务总监。在此之前，她曾在SoundBite Communications担任财务报告职务，2008年至2013年被Genesys收购；2004年至2008年在Cognex Corporation担任财务报告职务。罗曼诺的职业生涯始于普华永道波士顿办事处的一名审计师。她是马萨诸塞州的注册会计师，拥有圣十字学院会计学学士学位和波士顿学院会计学硕士学位。
Sarah Romano,was appointed to serve as First Wave Biopharma, Inc. Chief Financial Officer on March 1, 2022. Ms. Romano previously served as Chief Financial Officer of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (formerly EyeGate Pharmaceuticals, Inc.), a clinical-stage specialty pharmaceutical company developing products for treating ophthalmic diseases, from February 2017 through February 2022 and as its Corporate Controller from August 2016 to January 2017. Prior to joining Kiora, Ms. Romano served as Assistant Controller at TechTarget from June 2015 through August 2016 and Corporate Controller at Bowdoin Group, a healthcare-focused executive recruiting firm, from September 2013 through May 2015. Previously, she held financial reporting positions of increasing responsibility at SoundBite Communications from 2008 until its acquisition by Genesys in 2013, and at Cognex Corporation from 2004 through 2008. Ms. Romano began her career as an auditor in the Boston office of PricewaterhouseCoopers. A licensed CPA in Massachusetts, she holds a Bachelor of Arts in Accounting from College of the Holy Cross and a Master of Accounting from Boston College.- Sarah Romano于2022年3月1日被任命为First Wave Biopharma，Inc.的首席财务官。Romano女士曾于2017年2月至2022年2月担任Kiora Pharmaceuticals, Inc.（纳斯达克股票代码：KPRX）（原EyeGate Pharmaceuticals，Inc.）的首席财务官，并于2016年8月至2017年1月担任公司财务总监。Kiora Pharmaceuticals，Inc.是一家临床阶段的专业制药公司，致力于开发治疗眼科疾病的产品。在加入Kiora之前，Romano女士于2015年6月至2016年8月担任TechTarget助理财务总监，并于2013年9月至2015年5月担任专注于医疗保健的高管招聘公司Bowdoin Group的公司财务总监。在此之前，她曾在SoundBite Communications担任财务报告职务，2008年至2013年被Genesys收购；2004年至2008年在Cognex Corporation担任财务报告职务。罗曼诺的职业生涯始于普华永道波士顿办事处的一名审计师。她是马萨诸塞州的注册会计师，拥有圣十字学院会计学学士学位和波士顿学院会计学硕士学位。
- Sarah Romano,was appointed to serve as First Wave Biopharma, Inc. Chief Financial Officer on March 1, 2022. Ms. Romano previously served as Chief Financial Officer of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (formerly EyeGate Pharmaceuticals, Inc.), a clinical-stage specialty pharmaceutical company developing products for treating ophthalmic diseases, from February 2017 through February 2022 and as its Corporate Controller from August 2016 to January 2017. Prior to joining Kiora, Ms. Romano served as Assistant Controller at TechTarget from June 2015 through August 2016 and Corporate Controller at Bowdoin Group, a healthcare-focused executive recruiting firm, from September 2013 through May 2015. Previously, she held financial reporting positions of increasing responsibility at SoundBite Communications from 2008 until its acquisition by Genesys in 2013, and at Cognex Corporation from 2004 through 2008. Ms. Romano began her career as an auditor in the Boston office of PricewaterhouseCoopers. A licensed CPA in Massachusetts, she holds a Bachelor of Arts in Accounting from College of the Holy Cross and a Master of Accounting from Boston College.
- James Sapirstein
James Sapirstein，自2023年1月起担任Zyversa Therapeutics，Inc.董事会成员。Sapirstein先生目前是First Wave BioPharma公司（纳斯达克：FWBI）的董事长、首席执行官和总裁。Sapirstein先生的职业生涯始于较小的生物技术公司，后来他加入了吉利德科学公司，领导全球营销团队推出Viread（替诺福韦）。2002年，他接受了Serono实验室代谢和内分泌学执行副总裁的职位。后来，在2006年，他成为Tobira Therapeutics, Inc.的创始首席执行官，该公司当时是一家私营公司。Tobira Therapeutics于2016年被艾尔建收购。2012年，Sapirstein先生成为Alliqua，Inc.的首席执行官。此后，他从2014年3月至2018年10月担任Contravir Pharmaceuticals的首席执行官。所有这些都是上市公司。萨皮尔斯坦在担任首席执行官期间的各种活动中，通过风险资本和公开资本市场融资筹集了超过3亿美元。2015年和2016年，他都被提名为安永年度企业家奖的入围者。除了First Wave Bio Pharma的董事会成员，Sapirstein先生目前还在Enochian Biosciences公司（纳斯达克：ENOB）和Blue Water生物技术公司（纳斯达克：BWV）担任董事职务。2017年2月至2019年2月，他担任新泽西州生物制药行业协会BioNJ的董事会主席。此外，他还是BIO（生物技术创新组织）董事会成员，该组织是促进医疗保健领域公共政策和网络的领先生物技术贸易组织，他是该组织新兴公司科理事会成员。
James Sapirstein,has served as a director since March of 2018. Mr. Sapirstein joined the Board after having served over thirty-nine years in the pharmaceutical industry. He is currently the Chairman, President and CEO of First Wave BioPharma (formerly AzurRx BioPharma) and has served as the CEO of ContraVir Pharmaceuticals, Inc. (now Hepion), which is a company specializing in the Hepatitis B space. After beginning his career in 1984 with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its commercial teams in the US and abroad. He held a number of positions at Hoffmann-LaRoche before moving to Bristol Myers Squibb (BMS) in 1996 as the Director of International Marketing in the Infectious Disease group. While at BMS, he worked on several important HIV/AIDS projects, including Secure the Future. Later, Mr. Sapirstein started his career in smaller biotech companies when he joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir). In 2002, he accepted the position of Executive Vice President of Metabolic and Endocrinology for Serono Laboratories before becoming the founding CEO of Tobira Therapeutics in 2006. In 2012, after several years in the infectious diseases space, Mr. Sapirstein became the CEO of Alliqua Therapeutics at Alliqua, Inc. He is also a Board Director for the Emerging Companies Section Governing group of the Biotechnology Innovation Organization (BIO) and the Chairman Emeritus of BIO's New Jersey Chapter (BioNJ). Mr. Sapirstein received his MBA from Fairleigh Dickinson University and his B.Pharm. from Rutgers University.- James Sapirstein，自2023年1月起担任Zyversa Therapeutics，Inc.董事会成员。Sapirstein先生目前是First Wave BioPharma公司（纳斯达克：FWBI）的董事长、首席执行官和总裁。Sapirstein先生的职业生涯始于较小的生物技术公司，后来他加入了吉利德科学公司，领导全球营销团队推出Viread（替诺福韦）。2002年，他接受了Serono实验室代谢和内分泌学执行副总裁的职位。后来，在2006年，他成为Tobira Therapeutics, Inc.的创始首席执行官，该公司当时是一家私营公司。Tobira Therapeutics于2016年被艾尔建收购。2012年，Sapirstein先生成为Alliqua，Inc.的首席执行官。此后，他从2014年3月至2018年10月担任Contravir Pharmaceuticals的首席执行官。所有这些都是上市公司。萨皮尔斯坦在担任首席执行官期间的各种活动中，通过风险资本和公开资本市场融资筹集了超过3亿美元。2015年和2016年，他都被提名为安永年度企业家奖的入围者。除了First Wave Bio Pharma的董事会成员，Sapirstein先生目前还在Enochian Biosciences公司（纳斯达克：ENOB）和Blue Water生物技术公司（纳斯达克：BWV）担任董事职务。2017年2月至2019年2月，他担任新泽西州生物制药行业协会BioNJ的董事会主席。此外，他还是BIO（生物技术创新组织）董事会成员，该组织是促进医疗保健领域公共政策和网络的领先生物技术贸易组织，他是该组织新兴公司科理事会成员。
- James Sapirstein,has served as a director since March of 2018. Mr. Sapirstein joined the Board after having served over thirty-nine years in the pharmaceutical industry. He is currently the Chairman, President and CEO of First Wave BioPharma (formerly AzurRx BioPharma) and has served as the CEO of ContraVir Pharmaceuticals, Inc. (now Hepion), which is a company specializing in the Hepatitis B space. After beginning his career in 1984 with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its commercial teams in the US and abroad. He held a number of positions at Hoffmann-LaRoche before moving to Bristol Myers Squibb (BMS) in 1996 as the Director of International Marketing in the Infectious Disease group. While at BMS, he worked on several important HIV/AIDS projects, including Secure the Future. Later, Mr. Sapirstein started his career in smaller biotech companies when he joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir). In 2002, he accepted the position of Executive Vice President of Metabolic and Endocrinology for Serono Laboratories before becoming the founding CEO of Tobira Therapeutics in 2006. In 2012, after several years in the infectious diseases space, Mr. Sapirstein became the CEO of Alliqua Therapeutics at Alliqua, Inc. He is also a Board Director for the Emerging Companies Section Governing group of the Biotechnology Innovation Organization (BIO) and the Chairman Emeritus of BIO's New Jersey Chapter (BioNJ). Mr. Sapirstein received his MBA from Fairleigh Dickinson University and his B.Pharm. from Rutgers University.